Prosecution Insights
Last updated: April 19, 2026

Aslan Pharmaceuticals Pte Ltd

4 pending office actions

Portfolio Summary

4
Total Pending OAs
3
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18695502 METHOD FOR TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS LOCKARD, JON MCCLELLAND 1647 Final Rejection Mar 26, 2024
18695464 TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF LOCKARD, JON MCCLELLAND 1647 Final Rejection Mar 26, 2024
18042920 TREATMENT AND/OR PREVENTION OF A VIRAL INFECTION ROMERO, KRISTEN WANG 1624 Non-Final OA Feb 24, 2023
17929874 TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION BRISTOL, LYNN ANNE 1643 Final Rejection Sep 06, 2022

Managing Aslan Pharmaceuticals Pte Ltd's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month